Cooperative Agreement R43CA180323

This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...

This $476,999 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the Mayo Clinic's research on targeting the AXL receptor tyrosine kinase with a humanized anti-AXL monoclonal antibody as a novel therapy for ovarian cancer. The 4-year project aims to develop and evaluate this antibody-based treatment for ovarian cancer. As a leading non-profit academic medical center, Mayo Clinic leverages its expertise in...

The Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $778,092.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. This research aims to develop innovative immunotherapeutic approaches to achieve cures for this aggressive form of ovarian cancer. DFCI, a...

This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

This $795,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports Mayo Clinic's research to develop a humanized anti-AXL monoclonal antibody as a novel therapy for ovarian cancer. The 4-year project aims to target the AXL receptor tyrosine kinase as a potential new treatment approach. As an experienced biomedical research institution, Mayo Clinic will leverage its expertise in preclinical pharmacokinetic...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

Summary The National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) awarded a $683,970 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) beginning April 1, 2026, with completion targeted for March 31, 2031. This award supports research aimed at modifying the pancreatic cancer tumor microenvironment through the αvβ5 integrin pathway. The research focuses on developing and evaluating the IRGD tumor-penetrating peptide as a...

Summary of Federal Project Grant Award The National Cancer Institute (NCI) awarded the University of Louisville's Office of Research & Innovation $403,686 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel combination therapy for recurrent ovarian cancer. The award, effective May 1, 2026 through April 30, 2028, supports research addressing platinum-resistant ovarian cancer, which accounts for approximately 70% of recurrence cases within 18-24 months...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...